search
Back to results

Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

Primary Purpose

Post-Traumatic Stress Disorders, Major Depressive Disorder

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Ketamine
Normal Saline
Sponsored by
University of Minnesota
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Post-Traumatic Stress Disorders focused on measuring ketamine, stress disorders, post-traumatic, stress disorders, traumatic, anxiety disorders, mental disorders, adjuvants, anesthesia, analgesics, anesthetics, anesthetics, dissociative, anesthetics, general, anesthetics, intravenous, excitatory amino acid agents, excitatory amino acid antagonists, hypnotics and sedatives, molecular mechanisms of pharmacological action, neurotransmitter agents, peripheral nervous system agents, pharmacologic actions, physiological effects of drugs, psychotropic drugs, sensory system agents, central nervous system agents, central nervous system depressants, depression, depressive disorder, depressive disorder, treatment-resistant, behavioral symptoms, mood disorders, therapeutic uses

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

For the PTSD+MDD group, inclusion criteria are:

  1. Female/Male veterans
  2. 18 to 75 years old
  3. Meets DSM-5 criteria for MDD, single or recurrent, moderate-severe without psychotic features
  4. Meets DSM-5 criteria for chronic PTSD or subthreshold PTSD [meets criterion A (traumatic event), criterion B (intrusion symptoms), and 2 of the following 3 criteria: C (avoidance symptoms), D (negative alterations in cognitions and mood), or E (marked alterations in arousal and reactivity)]
  5. If applicable, 6 weeks of stable antidepressants/augmenting agents
  6. Sixth grade reading level
  7. Ability to provide consent

For the Healthy Controls group, inclusion criteria are:

  1. Female/Male veterans
  2. 18 to 75 years old
  3. Does not meet DSM-5 criteria for MDD, single or recurrent, moderate-severe without psychotic features
  4. Does not meet DSM-5 criteria for chronic PTSD or subthreshold PTSD
  5. Not on medications for managing a psychiatric indication
  6. Sixth grade reading level
  7. Ability to provide consent

For the Depression-only group, inclusion criteria are:

  1. Female/Male veterans
  2. 18 to 75 years old
  3. Experienced a traumatic event that meets DSM-5 criterion A for a diagnosis of PTSD but does not meet sufficient criteria (B-E) necessary for a diagnosis of PTSD or subthreshold PTSD
  4. Meets criteria for MDD, single or recurrent, moderate-severe
  5. If applicable, 6 weeks of stable antidepressants/augmenting agents
  6. Sixth grade reading level
  7. Ability to provide consent

For the PTSD-only group, inclusion criteria are:

  1. Female/Male veterans
  2. 18 to 75 years old
  3. Meets DSM-5 criteria for chronic PTSD or subthreshold PTSD [meets criterion A (traumatic event), criterion B (intrusion symptoms), and 2 of the following 3 criteria: C (avoidance symptoms), D (negative alterations in cognitions and mood), or E (marked alterations in arousal and reactivity)]
  4. Does not meet DSM-5 criteria for MDD, single or recurrent, moderate-severe without psychotic features
  5. If applicable, 6 weeks of stable antidepressants/augmenting agents
  6. Sixth grade reading level
  7. Ability to provide consent

Exclusion Criteria:

For the PTSD+MDD group, exclusion criteria are:

  1. Inability or unwillingness to provide written informed consent
  2. Moderate/severe cognitive impairment
  3. Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition
  4. History of moderate or severe traumatic brain injury
  5. History of comorbid substance disorder within 1 month of screening
  6. Prior use of ketamine as an antidepressant
  7. Clinically unstable medical illness
  8. For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study
  9. Imminent risk of suicidal/homicidal ideation and/or behavior
  10. Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.)

For the Healthy Controls group, exclusion criteria are:

  1. Inability or unwillingness to provide written informed consent
  2. Moderate/severe cognitive impairment
  3. History of any major medical or psychiatric disorders
  4. Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition
  5. History of moderate or severe traumatic brain injury
  6. History of comorbid substance disorder within 1 month of screening
  7. Prior use of ketamine as an antidepressant
  8. Clinically unstable medical illness
  9. For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study
  10. Imminent risk of suicidal/homicidal ideation and/or behavior
  11. Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.)

For the Depression-only group, exclusion criteria are:

  1. Inability or unwillingness to provide written informed consent
  2. Moderate/severe cognitive impairment
  3. Meet DSM-5 criteria for PTSD or subthreshold PTSD
  4. Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition
  5. History of moderate or severe traumatic brain injury
  6. History of comorbid substance disorder within 1 month of screening
  7. Prior use of ketamine as an antidepressant
  8. Clinically unstable medical illness
  9. For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study
  10. Imminent risk of suicidal/homicidal ideation and/or behavior
  11. Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.)

For the PTSD-only group, exclusion criteria are:

  1. Inability or unwillingness to provide written informed consent
  2. Moderate/severe cognitive impairment
  3. Meet DSM-5 criteria for a diagnosis of MDD, single or recurrent, moderate to severe
  4. Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition
  5. History of moderate or severe traumatic brain injury
  6. History of comorbid substance disorder within 1 month of screening
  7. Prior use of ketamine as an antidepressant
  8. Clinically unstable medical illness
  9. For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study
  10. Imminent risk of suicidal/homicidal ideation and/or behavior
  11. Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.)

Sites / Locations

  • Minneapolis Veterans Affairs Health Care SystemRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Intravenous ketamine infusions

Intravenous saline infusions

Arm Description

Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.

Six infusions of normal saline solution over 3 weeks.

Outcomes

Primary Outcome Measures

Montgomery-Asberg Depression Rating Scale (MADRS)
Change in major depressive disorder symptoms over the course of the intervention.
PTSD Symptom Scale-Interview for DSM-5 (PSS-I-5)
Change in post-traumatic stress disorder symptoms over the course of the intervention.

Secondary Outcome Measures

Full Information

First Posted
June 26, 2019
Last Updated
February 5, 2023
Sponsor
University of Minnesota
Collaborators
Minneapolis Veterans Affairs Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04032301
Brief Title
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
Official Title
Characterization of Comorbid Post-traumatic Stress Disorder and Major Depressive Disorder Utilizing Ketamine as an Experimental Medicine Probe
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 30, 2019 (Actual)
Primary Completion Date
April 1, 2024 (Anticipated)
Study Completion Date
April 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Minnesota
Collaborators
Minneapolis Veterans Affairs Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability. Veterans with both PTSD and MDD (PTSD+MDD) have been shown to be at much greater suicidal risk than individuals with only one of these disorders. Ketamine given as repeated infusions has been shown to be effective in rapidly reducing PTSD and MDD symptoms in treatment resistant PTSD+MDD individuals. However, knowledge about the mechanisms underlying comorbid PTSD and MDD remain limited. The purpose of this study is to use repeated ketamine infusions as a probe to validate a model of PTSD+MDD that focuses on neuroanatomy and executive functioning.
Detailed Description
This study is designed to better characterize the neurocognitive and associated functional connectivity mechanisms underlying comorbid post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) among veterans. Participants will be male/female veterans (18 to 75 years old) of any era or military background who suffer from chronic PTSD and MDD. Potential participants will be recruited from mental health clinics and screened for eligibility using a two stage process (phone/chart review, followed by interview). Participants with PTSD+MDD will undergo a series of baseline assessments including a baseline functional magnetic resonance imaging (fMRI) then be randomized to receive either 6 ketamine or 6 normal saline infusions on a Monday-Friday schedule over 3 weeks. On the day of infusion, participants will be required to stay at the clinical site for 2 hours after the infusion has been given. They will also be monitored via a phone call on the following day. After the infusion period has been completed participants will undergo a follow-up fMRI then 4 follow-up visits, up to 2 months. Additional participants will be enrolled in healthy control, depression only, and PTSD only groups and will only undergo baseline assessments, including a single fMRI.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post-Traumatic Stress Disorders, Major Depressive Disorder
Keywords
ketamine, stress disorders, post-traumatic, stress disorders, traumatic, anxiety disorders, mental disorders, adjuvants, anesthesia, analgesics, anesthetics, anesthetics, dissociative, anesthetics, general, anesthetics, intravenous, excitatory amino acid agents, excitatory amino acid antagonists, hypnotics and sedatives, molecular mechanisms of pharmacological action, neurotransmitter agents, peripheral nervous system agents, pharmacologic actions, physiological effects of drugs, psychotropic drugs, sensory system agents, central nervous system agents, central nervous system depressants, depression, depressive disorder, depressive disorder, treatment-resistant, behavioral symptoms, mood disorders, therapeutic uses

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
Experimental versus Placebo
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
108 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intravenous ketamine infusions
Arm Type
Experimental
Arm Description
Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
Arm Title
Intravenous saline infusions
Arm Type
Placebo Comparator
Arm Description
Six infusions of normal saline solution over 3 weeks.
Intervention Type
Drug
Intervention Name(s)
Ketamine
Other Intervention Name(s)
Ketamine Hydrochloride
Intervention Description
Six infusions of intravenous 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
Intervention Type
Other
Intervention Name(s)
Normal Saline
Other Intervention Name(s)
Sodium Chloride in Water
Intervention Description
Six infusions of intravenous normal saline solution over 3 weeks.
Primary Outcome Measure Information:
Title
Montgomery-Asberg Depression Rating Scale (MADRS)
Description
Change in major depressive disorder symptoms over the course of the intervention.
Time Frame
At baseline, 60 minutes pre-infusion, 24 hours post-infusion, and after infusion series up to 2 months.
Title
PTSD Symptom Scale-Interview for DSM-5 (PSS-I-5)
Description
Change in post-traumatic stress disorder symptoms over the course of the intervention.
Time Frame
At baseline, 60 minutes pre-infusion, 24 hours post-infusion, and after infusion series up to 2 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: For the PTSD+MDD group, inclusion criteria are: Female/Male veterans 18 to 75 years old Meets DSM-5 criteria for MDD, single or recurrent, moderate-severe without psychotic features Meets DSM-5 criteria for chronic PTSD or subthreshold PTSD [meets criterion A (traumatic event), criterion B (intrusion symptoms), and 2 of the following 3 criteria: C (avoidance symptoms), D (negative alterations in cognitions and mood), or E (marked alterations in arousal and reactivity)] If applicable, 6 weeks of stable antidepressants/augmenting agents Sixth grade reading level Ability to provide consent For the Healthy Controls group, inclusion criteria are: Female/Male veterans 18 to 75 years old Does not meet DSM-5 criteria for MDD, single or recurrent, moderate-severe without psychotic features Does not meet DSM-5 criteria for chronic PTSD or subthreshold PTSD Not on medications for managing a psychiatric indication Sixth grade reading level Ability to provide consent For the Depression-only group, inclusion criteria are: Female/Male veterans 18 to 75 years old Experienced a traumatic event that meets DSM-5 criterion A for a diagnosis of PTSD but does not meet sufficient criteria (B-E) necessary for a diagnosis of PTSD or subthreshold PTSD Meets criteria for MDD, single or recurrent, moderate-severe If applicable, 6 weeks of stable antidepressants/augmenting agents Sixth grade reading level Ability to provide consent For the PTSD-only group, inclusion criteria are: Female/Male veterans 18 to 75 years old Meets DSM-5 criteria for chronic PTSD or subthreshold PTSD [meets criterion A (traumatic event), criterion B (intrusion symptoms), and 2 of the following 3 criteria: C (avoidance symptoms), D (negative alterations in cognitions and mood), or E (marked alterations in arousal and reactivity)] Does not meet DSM-5 criteria for MDD, single or recurrent, moderate-severe without psychotic features If applicable, 6 weeks of stable antidepressants/augmenting agents Sixth grade reading level Ability to provide consent Exclusion Criteria: For the PTSD+MDD group, exclusion criteria are: Inability or unwillingness to provide written informed consent Moderate/severe cognitive impairment Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition History of moderate or severe traumatic brain injury History of comorbid substance disorder within 1 month of screening Prior use of ketamine as an antidepressant Clinically unstable medical illness For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study Imminent risk of suicidal/homicidal ideation and/or behavior Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.) For the Healthy Controls group, exclusion criteria are: Inability or unwillingness to provide written informed consent Moderate/severe cognitive impairment History of any major medical or psychiatric disorders Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition History of moderate or severe traumatic brain injury History of comorbid substance disorder within 1 month of screening Prior use of ketamine as an antidepressant Clinically unstable medical illness For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study Imminent risk of suicidal/homicidal ideation and/or behavior Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.) For the Depression-only group, exclusion criteria are: Inability or unwillingness to provide written informed consent Moderate/severe cognitive impairment Meet DSM-5 criteria for PTSD or subthreshold PTSD Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition History of moderate or severe traumatic brain injury History of comorbid substance disorder within 1 month of screening Prior use of ketamine as an antidepressant Clinically unstable medical illness For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study Imminent risk of suicidal/homicidal ideation and/or behavior Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.) For the PTSD-only group, exclusion criteria are: Inability or unwillingness to provide written informed consent Moderate/severe cognitive impairment Meet DSM-5 criteria for a diagnosis of MDD, single or recurrent, moderate to severe Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition History of moderate or severe traumatic brain injury History of comorbid substance disorder within 1 month of screening Prior use of ketamine as an antidepressant Clinically unstable medical illness For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study Imminent risk of suicidal/homicidal ideation and/or behavior Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alyssa Krueger, BS
Phone
612-467-1829
Email
Alyssa.Krueger@va.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Cristina S Albott, MD, MA
Phone
612-629-7124
Email
Cristina.Albott@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cristina S Albott, MD, MA
Organizational Affiliation
Minneapolis Veterans Affairs Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Minneapolis Veterans Affairs Health Care System
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55417
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alyssa Krueger, BS
First Name & Middle Initial & Last Name & Degree
Christina S Albott, MD, MA

12. IPD Sharing Statement

Learn more about this trial

Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

We'll reach out to this number within 24 hrs